UBS maintains Neutral rating for RIVN stock with upgraded price target of $13. Long-term outlook positive due to upcoming R2 launch.
Latest Ratings for RIVN
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 2022 | Wedbush | Maintains | Outperform | |
| Mar 2022 | Wells Fargo | Maintains | Equal-Weight | |
| Mar 2022 | RBC Capital | Maintains | Outperform |
